Abstract

In previous grant cycles, the ADCS has not played a major role in biomarker measurement;assays for Apolipoprotein E (ApoE) genotype, and for plasma and CSF measurement of amyloid peptides and tau proteins have been subcontracted to companies or external academic labs. However, the importance of biomarker measurement has grown steadily, in part due to the success of the Alzheimer's Disease Neuroimaging Initiative. There have been an increasing number of requests for stored ADCS samples, and increasing requests for biomarker measurement from ADCS investigators. To meet these needs, in late 2008, we established a Biomarker Core which is located on the 3rd floor of the Medical Teaching Facility building at UCSD School of Medicine.

Public Health Relevance

The goal of the laboratory is to identify biomarkers for preclinical AD and better understand how treatment parameters may impact these biomarkers. In addition to playing a role in ADCS clinical trials, another objective of the Biomarker Core is research based and aims to identify and characterize novel biomarkers of AD. The primary focus of this research is on plasma beta-amyloid.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program--Cooperative Agreements (U19)
Project #
2U19AG010483-22
Application #
8461390
Study Section
Special Emphasis Panel (ZAG1-ZIJ-7 (02))
Project Start
Project End
Budget Start
2012-12-31
Budget End
2013-11-30
Support Year
22
Fiscal Year
2013
Total Cost
$282,984
Indirect Cost
$77,605

  Institution

Name
University of California San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093

  Publications

Besser, Lilah; Kukull, Walter; Knopman, David S et al. (2018) Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set. Alzheimer Dis Assoc Disord 32:351-358
Jacobs, Heidi I L; Hedden, Trey; Schultz, Aaron P et al. (2018) Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals. Nat Neurosci 21:424-431
Buckley, Rachel F; Mormino, Elizabeth C; Amariglio, Rebecca E et al. (2018) Sex, amyloid, and APOE ?4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-characterized cohorts. Alzheimers Dement 14:1193-1203
Langa, Kenneth M; Larson, Eric B; Crimmins, Eileen M et al. (2017) A Comparison of the Prevalence of Dementia in the United States in 2000 and 2012. JAMA Intern Med 177:51-58
Jacobs, Diane M; Ard, M Colin; Salmon, David P et al. (2017) Potential implications of practice effects in Alzheimer's disease prevention trials. Alzheimers Dement (N Y) 3:531-535
Marquié, Marta; Verwer, Eline E; Meltzer, Avery C et al. (2017) Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's case. Acta Neuropathol Commun 5:75
Dekhtyar, Maria; Papp, Kathryn V; Buckley, Rachel et al. (2017) Neuroimaging markers associated with maintenance of optimal memory performance in late-life. Neuropsychologia 100:164-170
Schultz, Aaron P; Chhatwal, Jasmeer P; Hedden, Trey et al. (2017) Phases of Hyperconnectivity and Hypoconnectivity in the Default Mode and Salience Networks Track with Amyloid and Tau in Clinically Normal Individuals. J Neurosci 37:4323-4331
Vannini, Patrizia; Hanseeuw, Bernard; Munro, Catherine E et al. (2017) Anosognosia for memory deficits in mild cognitive impairment: Insight into the neural mechanism using functional and molecular imaging. Neuroimage Clin 15:408-414
Donohue, Michael C; Sperling, Reisa A; Petersen, Ronald et al. (2017) Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons. JAMA 317:2305-2316

Showing the most recent 10 out of 490 publications